Skysona

Indicated For

cerebral adrenoleukodystrophy, CALD, ALD

About This Medication

# my bluebird support Patient Guide: How to Get Skysona (elivaldogene autotemcel) at Low or No Cost Skysona (elivaldogene autotemcel) is a one-time gene therapy from **bluebird bio** designed to slow the progression of neurologic dysfunction in boys aged 4-17 with early, active cerebral adrenoleukodystrophy (CALD), a rare and serious brain condition caused by mutations in the *ABCD1* gene.[3][4] The **my bluebird support** program provides comprehensive assistance, including a dedicated Patient Navigator to guide families through insurance navigation, finding Qualified Treatment Centers (QTCs), and financial support options for eligible patients—available at no cost with no obligation to proceed with treatment.[1][2][8] ## About Skysona and Cerebral Adrenoleukodystrophy (CALD) **CALD** is a devastating form of adrenoleukodystrophy that affects boys, leading to brain damage, cognitive decline, and potentially fatal outcomes if untreated. Early, active CALD is defined as asymptomatic or mildly symptomatic boys (Neurologic Function Score ≤1) with gadolinium enhancement on brain MRI and Loes scores of 0.5-9.[3] Skysona works by delivering functional copies of the *ABCD1* gene into the patient's own hematopoietic stem cells via a lentiviral vector, which are then infused back after a conditioning regimen.[4][6] This is a **one-time, autologous (uses the patient's own cells) gene therapy** administered at a specialized Qualified Treatment Center (QTC).[7] It's FDA-approved but carries a **boxed warning** for hematologic malignancies like myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), with cases reported in 3 of 67 treated patients (4% incidence).[5][10] Recent FDA restrictions (as of 2025) limit use to CALD patients without suitable alternatives, such as HLA-matched stem cell donors, due to these safety concerns.[4][5] Treatment is hospital-administered, covered under HCPCS code J3387, and considered a lifetime one-time therapy.[6] Costs can exceed $3 million, making support programs essential.[10] ## Who Qualifies for my bluebird support? my bluebird support is open to **eligible U.S. residents** (including territories) considering Skysona, with no specific income thresholds detailed publicly—instead, eligibility focuses on medical criteria and insurance status.[8] Key qualifiers include: - Boys aged **4-17 years** with confirmed **early, active CALD** (gadolinium-enhancing lesions on MRI, Loes score 0.5-9, NFS ≤1).[3][6] - No available HLA-matched allogeneic hematopoietic stem cell transplant donor.[4] - Enrollment via healthcare provider (HCP) using the Program Enrollment Form.[2][8] The program connects you to a **Patient Navigator** for education, QTC referrals, and financial assistance navigation. It's not a traditional copay card but holistic support, potentially including free drug access for uninsured/underinsured via manufacturer channels.[1][8] **Income Eligibility Breakdown** Specific FPL-based thresholds are not publicly listed for my bluebird support; eligibility is primarily medical and insurance-driven. Patient Navigators assess case-by-case. Here's a general table for context on similar gene therapy programs (consult Navigator for Skysona specifics): | Household Size | Typical Threshold (e.g., 400-500% FPL) | Annual Income Example (2026) | |----------------|---------------------------------------|------------------------------| | Individual | ~$60,000-$75,000 | Varies by program | | Couple | ~$80,000-$100,000 | Case-by-case | | Family of 3 | ~$100,000-$125,000 | Navigator assessment | | Family of 4 | ~$120,000-$150,000 | Medical need prioritized | *Note: my bluebird support emphasizes medical necessity over strict income; contact for personalized review.[1][2]* ## Insurance Requirements Skysona requires **prior authorization** from most insurers, including commercial, Medicare Advantage, and Qualified Health Plans.[6][9] Coverage criteria mirror FDA indications: age 4-17, active early CALD, no donor alternative.[6] It's a **lifetime benefit** (one treatment).[6] - **Commercial/Medicaid**: HCP submits to payer; QTCs assist.[7] - **Medicare**: Limited coverage; gene therapies like Skysona often require exceptions. Patient Navigator helps appeal denials.[1] - **Uninsured**: my bluebird support explores manufacturer-sponsored free drug programs.[8] Blue Shield and Mass General policies confirm hospital administration with strict medical criteria.[6][9] ## Step-by-Step Application Process 1. **Consult HCP**: Discuss Skysona suitability; confirm CALD diagnosis via MRI, Loes score, etc.[3][6] 2. **HCP Initiates Enrollment**: Fax completed Program Enrollment Form to 1-844-999-6378.[2] 3. **Patient Navigator Contact**: They'll call to explain program, confirm interest, provide resources.[1][2][8] 4. **Find QTC**: Navigator helps locate a Qualified Treatment Center for evaluation.[1][7] 5. **Insurance Verification**: Navigator assists with benefits investigation, prior auth.[1] 6. **Financial Assessment**: Discuss copay assistance, free drug if eligible. Call (833) 888-6378.[2] 7. **Treatment**: If approved, proceed to cell collection, manufacturing, infusion at QTC.[3] Application method: Phone (833) 888-NEST/(6378) or HCP fax.[2][8] ## Timeline and Delivery Processing varies; no fixed timeline public. Expect: - Enrollment to Navigator contact: Days.[2] - QTC evaluation/prior auth: Weeks to months.[1] - Manufacturing: Several weeks (custom cells).[6] - Total from enrollment to infusion: 2-6 months, depending on insurance.[1] Delivery: Infused intravenously at hospital/QTC; no home delivery. One-time only.[6][7] ## Alternatives if Denied - **Allogeneic HSCT**: Preferred if HLA-matched sibling donor available (safer, no malignancy risk).[4] - **Clinical trials**: Check ClinicalTrials.gov for CALD studies. - **Other therapies**: Supportive care (steroids, Lorenzo's oil—limited efficacy). - **Appeal**: Navigator helps with denials; biosimilars: None available.[1] - **Safety note**: FDA restricts to no-alternative cases due to cancer risk.[5] ## Disclaimer This guide is for informational purposes only and not medical/financial advice. Eligibility, coverage, and risks vary. **Skysona has serious risks, including blood cancers (MDS/AML in ~4% of patients)**—discuss with HCP.[5][10] Contact my bluebird support at (833) 888-6378 for latest details. bluebird bio oversees program but not QTC care.[7] Word count: 1028.

Program information last verified: March 30, 2026